Mini-reviewTumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Highlights
► Breast cancer development largely relies on the microenvironment. ► TAMs accumulate in breast cancer microenvironment and facilitate cancer development. ► TAMs represent as a potential diagnostic and prognostic biomarker in human breast cancers.
Introduction
Breast cancer is the most prevalent malignant disease of women in the developed world, excluding the non-melanoma skin cancers, and is one of the leading causes of death among women. Approximately, 1 in 8 women in the United States are diagnosed with breast cancer at some time in their lives. After slowly increasing for many years (0.4% annually from 1975 to 1990), breast cancer mortality decreased by 2.2% per year from 1990 to 2007 [1]. Declines in breast cancer mortality have been attributed to both improvements in treatment (adjuvant chemotherapy as well as radiation, hormonal and targeted therapies) and early detection (better characterization of diagnostic and prognostic factors) [2]. However, not all populations have benefited from those advances, and the morbidity and mortality is still high. Therefore, there are a number of hard nuts to crack before we could defeat breast cancers completely. On one hand, it is required to explore novel drugs and strategies for the treatment of breast cancer. On the other hand, new adjuvant diagnostic and prognostic biomarkers in combination with current parameters are required to make better treatment decisions.
As technologies advance, we are rapidly approaching an integrated understanding of breast cancer, from the origin and genetic alternations that license uncontrolled cell proliferation, to the unique contribution of the tumor microenvironments that support or reduce malignancy [3]. Genetically, current genome-wide association studies (GWAS) have identified amount of single nucleotide polymorphisms (SNPs) in women with breast cancer [4], [5], [6], [7]. The functions of some SNPs have been uncovered [6], and the assessment of those SNPs could be used for the identification of individuals with higher risk of developing breast cancer. On the other hand, the tumor microenvironment has been increasingly considered as a therapeutic target or biomarker for diagnosis and prognosis. The microenvironment of breast cancer is populated by many cells including the adipocytes, fibroblasts, a wide range of hematopoietic cells, as well as newly formed blood and lymphatic vessels and their associated cells [8], most of which participate as abettors or double-edged swords in breast carcinogenesis. Among those cells, the tumor-associated macrophages (TAMs) represent a predominant component of the tumor mass in breast carcinoma, and appear to be a pivotal orchestrator.
Macrophages have remarkable plasticity that allows them to efficiently respond to environmental signals and change their phenotype, and their physiology can be markedly altered by both innate and adaptive immune responses [9]. In an effort to emulate the T-cell literature, macrophages have been classified along what could be viewed as linear scale, on which classically activated macrophages (M1) represent one extreme and alternatively activated macrophages (M2) represent the other [9], [10]. M1 macrophages are pro-inflammatory and characterized by high expression of pro-inflammatory factors, such as interleukin (IL)-12, nitric oxide synthase 2 (NOS2), tumor necrosis factor (TNF)-α, and by high microbicidal and tumoricidal activity [11]. Conversely, M2 macrophages are immunosuppressive and produce high levels of anti-inflammatory cytokines, such as IL-10, transforming growth factor (TGF)-β, and low levels of pro-inflammatory cytokines. Nevertheless, this dichotomy may not be so clear cut in vivo, as some populations exhibit both the M1 and M2 behaviors, depending on the certain physiological and pathological conditions and the microenvironment. Investigators have implicated that macrophages participate in a range of physiologic and pathological processes, including homeostasis, inflammation, repair, metabolic functions, and malignancy [10], [11], [12], [13]. Biswas and Mantovani currently reviewed the functions and mechanisms of M1 and M2 macrophages [14].
Macrophages continuously infiltrate into the tumor microenvironment, where breast cancer cells and other infiltrates release factors that induce macrophages to TAMs. TAMs are a heterogeneous population, both in human and mouse, whereby distinct subsets perform distinct functions [15], [16], [17]. Among TAM subpopulations in tumor sites, some populations are highly M2-activated, CD163 and CD206-positive, and express amount of tumor-promoting cytokines and growth factors [17], [18]. Once activated, M2-like TAMs facilitate breast tumor growth, angiogenesis, metastasis, matrix remodelling and immune evasion by releasing a variety of cytokines, including chemokines, inflammatory and growth factors [8], [19], [20], [21]. In contrast, M1-like macrophages have the potential to contribute to the earliest stages of neoplasia, primarily because the free radicals that they produce can lead to the DNA damage; this causes mutations that can predispose host cells to transform [9]. Nevertheless, as tumors progress and grow, the tumor microenvironment markedly influences TAMs, the majority of which exhibit M2-like pro-tumoral properties, whereas the inflammatory M1-like macrophages behave as scavengers. TAMs act as a double-edged sword but a pivotal orchestrator in breast cancer development. As a matter of fact, TAMs have now been considered as potential targets for adjuvant therapy [22]. Either depletion of TAMs or reversion of their pro-tumoral properties (M2 to M1) has been demonstrated to reject tumor progression in mouse models of breast cancer [23], [24], [25], [26], [27].
More importantly, clinical evidences show that TAMs significantly correlate with micro-vessel density, lymph-node, hormone receptor (HR) status and tumor grades, and predict the efficacy of treatment and the survival in breast cancer patients. Therefore, TAMs is a novel candidate for targeted cancer therapy and prognostic biomarker of response and clinical benefit. Here in this article, we will review the available information on TAMs in diagnosis and prognosis for breast cancers.
Section snippets
CD68
Early in the late 1970s, Wood and Gollahon [28] have observed the presence of macrophages (as measured by presence of the Fc [IgG] receptor) in breast tumor microenvironment that determined the risk of disease progression and therapeutic resistance. Further, Steele et al. [29] confirmed the existence of macrophages using four surface markers: the receptors for the Fc portion of IgG and for C3, HLA-DR antigen, and a macrophage-associated antigen (defined by the mouse monoclonal antibody VEP-7).
Clinical detection of TAM signature
When it comes to clinical practice, macrophage detection is important. Logically, two strategies are available. One approach is to exam the density, polarization and micro-localization of TAMs by staining macrophage markers in biopsy samples. As TAMs are heterogeneous cells that can adopt different phenotypes depending on the microenvironment context. CD68 (or other pan-macrophage markers) alone could not represent the pro-tumoral or tumoricidal TAMs. Immunohistochemical double-staining of
Conclusion and prospects
Increasing clinical investigations have indicated that TAMs are significantly correlated with the progress of invasive ductal breast cancers and predict the prognosis of cancer patients. Generally, high density of TAMs predicts high tumor grade, HR-negativity, lymph node and distant metastasis, reduced recurrence-free and overall survival.
TAMs are highly heterogeneous, the tumoricidal M1 macrophages and some other infiltrating cells are also CD68-positive (or HAM-56-positive or CD14-positive).
Acknowledgements
We thank Cechuan Deng and Xiaoyong Huang of West China Hospital, Sichuan University and Limei Wang of Tsinghua University for their critical reading of this manuscript and great suggestions. We apologize to all researchers whose relevant contributions were not cited due to space limitations.
References (89)
- et al.
Association analysis between breast cancer genetic variants and mammographic density in a large population-based study (Determinants of Density in Mammographies in Spain) identifies susceptibility loci in TOX3 gene
Eur. J. Cancer
(2013) - et al.
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages
Crit. Rev. Oncol. Hematol.
(2008) - et al.
Alternative activation of macrophages: mechanism and functions
Immunity
(2010) - et al.
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer
Am. J. Pathol.
(2010) - et al.
Tumour-associated macrophages in breast cancer and their prognostic correlations
Breast
(1998) - et al.
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3
Cancer Cell
(2011) - et al.
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma
Pathol. Res. Pract.
(1995) - et al.
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy
J. Pharm. Biomed. Anal.
(2007) - et al.
High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors
Am. J. Pathol.
(2009) - et al.
Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813
Biomaterials
(2010)
Breast cancer statistics, 2011
CA. Cancer J. Clin.
Effect of screening and adjuvant therapy on mortality from breast cancer
New Engl. J. Med.
Heterogeneity in breast cancer
J. Clin. Invest.
Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African American women
Carcinogenesis
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression
Nat. Genet.
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers
Breast Cancer Res. Treat.
Macrophages define the invasive microenvironment in breast cancer
J. Leukocyte Biol.
Exploring the full spectrum of macrophage activation
Nat. Rev. Immunol.
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms
J. Immunol.
Alternative activation of macrophages: an immunologic functional perspective
Annu. Rev. Immunol.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Nat. Immunol.
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
Cancer Res.
Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors
J. Immunol.
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy
Dis. Model Mech.
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
Int. J. Dev. Biol.
Tumor-associated macrophages in breast cancer
J. Mammary Gland Biol. Neoplasia
Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics
Expert Rev. Mol. Diagn.
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
Int. J. Dev. Biol.
Anti-tumour strategies aiming to target tumour-associated macrophages
Immunology
Targeting tumor-associated macrophages as a novel strategy against breast cancer
J. Clin. Invest.
Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression
PLoS ONE
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages
Cancer Res.
Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression
Cancer Res.
Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)
Int. J. Cancer
Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell-surface markers
J. Natl. Cancer Inst.
Characterisation of macrophages infiltrating human mammary carcinomas
Br. J. Cancer
Macrophages in human breast disease: a quantitative immunohistochemical study
Br. J. Cancer
Leukocyte composition of human breast cancer
Proc. Natl. Acad. Sci. USA
Expression of CD68 in non-myeloid cell types
Scand. J. Immunol.
Cellular neurothekeoma with histiocytic differentiation
J. Cutan. Pathol.
The histiocytic marker PG-M1 is helpful in differentiating histiocytes and histiocytic tumors from melanomas
Appl. Immunohisto. Mol. Morphol.
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
Cancer Res.
Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density
Oncol. Rep.
Tumour-infiltrating macrophages and clinical outcome in breast cancer
J. Clin. Pathol.
Cited by (224)
HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization
2023, Biomedicine and PharmacotherapyEffect of metabolism on the immune microenvironment of breast cancer
2023, Biochimica et Biophysica Acta - Reviews on CancerIdentification of a novel macrophage-related prognostic signature in colorectal cancer
2024, Scientific ReportsHypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis
2024, Cell Communication and Signaling